Mankind Pharma Limited (NSE:MANKIND)
India
· Delayed Price · Currency is INR | Market Cap | 936.58B |
| Revenue (ttm) | 139.14B |
| Net Income (ttm) | 17.79B |
| Shares Out | 412.83M |
| EPS (ttm) | 43.10 |
| PE Ratio | 52.51 |
| Forward PE | 40.48 |
| Dividend | 2.00 (0.09%) |
| Ex-Dividend Date | n/a |
| Volume | 286,612 |
| Average Volume | 498,941 |
| Open | 2,269.00 |
| Previous Close | 2,268.70 |
| Day's Range | 2,242.60 - 2,280.00 |
| 52-Week Range | 1,909.70 - 2,716.50 |
| Beta | 0.39 |
| RSI | 66.76 |
| Earnings Date | May 22, 2026 |
About Mankind Pharma
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin a... [Read more]
Financial Performance
In fiscal year 2025, Mankind Pharma's revenue was 122.07 billion, an increase of 18.98% compared to the previous year's 102.60 billion. Earnings were 19.91 billion, an increase of 4.08%.
Financial StatementsNews
Mankind Pharma Transcript: Q3 25/26
Revenue and profit grew year-over-year, driven by strong chronic therapy and export performance, while acute and OTC segments are recovering post-restructuring. Working capital and debt metrics improved, and management expects double-digit growth ahead.
Mankind Pharma Transcript: Q2 25/26
Revenue grew 21% year-over-year in Q2 FY26, with EBITDA margin at 25%. BSV and exports drove strong growth, while GST disruptions and higher costs impacted margins. Guidance for full-year EBITDA margin and BSV growth is maintained, with recovery expected in H2.
Mankind Pharma Transcript: Q1 25/26
Q1 FY26 saw 24.5% revenue growth and 23.8% EBITDA margin, with strong domestic and international performance, though net profit declined 17.4% due to higher finance and depreciation costs. Guidance for margins and growth remains unchanged, with BSV expected to accelerate in H2.
Mankind Pharma Transcript: Q4 24/25
Revenue grew 27% YoY in Q4 and 19% for FY25, with strong chronic and consumer healthcare performance. Adjusted EBITDA margin improved to 25.9% for FY25, and VSC integration is expected to drive further growth and synergies. Guidance remains robust for FY26.
Mankind Pharma Transcript: Q3 24/25
Q3 and 9M FY25 saw strong revenue and margin growth, driven by BSV integration, chronic and OTC outperformance, and robust exports. Corrective actions in field force and leadership led to temporary volume softness but improved margins. Synergies from BSV and further margin expansion are expected.
Mankind Pharma Transcript: Q2 24/25
Q2 FY25 saw 14% revenue growth and 27.7% EBITDA margin, driven by chronic and OTC segments, with BSV acquisition expanding specialty presence. Debt for the acquisition is set to be retired within three years through equity and asset sales, while double-digit growth and margin improvement are guided.
Mankind Pharma Transcript: Q1 24/25
Q1 FY25 saw 12% revenue growth, 25.2% adjusted EBITDA margin, and strong cash generation. Chronic and consumer healthcare segments outperformed, while the BSV acquisition and Panacea integration are expected to drive future growth and margin expansion.